Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maria Rikala, Helena Kastarinen, Pekka Tiittanen, Risto Huupponen & Maarit Jaana Korhonen. (2016) Natural history of bleeding and characteristics of early bleeders among warfarin initiators – a cohort study in Finland. Clinical Epidemiology 8, pages 23-35.
Read now
Read now
Felix Schiele, Joanne van Ryn, Tobias Litzenburger, Michael Ritter, Daniel Seeliger & Herbert Nar. (2015) Structure-guided residence time optimization of a dabigatran reversal agent. mAbs 7:5, pages 871-880.
Read now
Read now
Jinan Liu, Gosia Sylwestrzak, John Barron, Alan Rosenberg, Jeffrey White, John Whitney, Rita Redberg & David Malenka. (2014) Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured. Current Medical Research and Opinion 30:9, pages 1707-1713.
Read now
Read now
Alpesh Amin. (2013) Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clinical Interventions in Aging 8, pages 75-84.
Read now
Read now
Articles from other publishers (44)
Camille Brod, Nicole Groth, Macaela Rudeck, Ramin Artang, Matthew Rioux & Catherine Benziger. (2023) Oral anticoagulation use in non-valvular atrial fibrillation patients in rural setting. American Journal of Medicine Open 9, pages 100026.
Crossref
Crossref
Cormac Kennedy, Caitriona Ni Choitir, Sarah Clarke, Kathleen Bennett & Michael Barry. (2020) Direct oral anticoagulants uptake and an oral anticoagulation paradox. British Journal of Clinical Pharmacology 86:2, pages 392-397.
Crossref
Crossref
Haseeb Saeed, Oscar Garza Ovalle, Ujala Bokhary, Anastasia Jermihov, Kamila Lepkowska, Victoria Bauer, Kristine Kuchta, Marcia Wright, Scott Glosner, Margaret Frazer, Andres Quintero, Patrick Hlavacek, Jack Mardekian, Alfonso Tafur, Mark Metzl & Jorge Saucedo. (2020) National Physician Survey for Nonvalvular Atrial Fibrillation (NVAF) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs. Clinical and Applied Thrombosis/Hemostasis 26, pages 107602962095255.
Crossref
Crossref
Thang S Han, Christopher Henry Fry, David Fluck, Brendan Affley, Giosue Gulli, Christopher Barrett, Puneet Kakar, Tasmin Patel, Sapna Sharma & Pankaj Sharma. (2018) Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK. BMJ Open 8:7, pages e022558.
Crossref
Crossref
I Induruwa, E Amis, N Hannon & K Khadjooi. (2017) The Increasing Burden of Atrial Fibrillation in Acute Medical Admissions, An Opportunity to Optimise Stroke Prevention. Journal of the Royal College of Physicians of Edinburgh 47:4, pages 331-335.
Crossref
Crossref
Ping G. TepperXianchen LiuMelissa HamiltonJack MardekianWilliam PetkunWilson TanDaniel E. Singer. (2017) Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation. Stroke 48:6, pages 1487-1494.
Crossref
Crossref
Ariela R. Orkaby, Al Ozonoff, Joel I. Reisman, Donald R. Miller, Shibei Zhao & Adam J. Rose. (2016) Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. Journal of the American Geriatrics Society 65:2, pages 249-256.
Crossref
Crossref
Peter Y. S. Ong, Narendran Koomanan, McVin H. H. Cheen, Yi Feng Lai, Seng Han Lim, Ming Chai Kong & Heng Joo Ng. (2016) Real-World Impact of Setting a Narrow International Normalized Ratio Target Range in the Management of Older Adult Patients on Warfarin. Clinical and Applied Thrombosis/Hemostasis 22:6, pages 528-534.
Crossref
Crossref
Michael H. Kim, Qiang Cai, Liou Xu & Gary A. Puckrein. (2016) Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level. Advances in Therapy 33:9, pages 1579-1599.
Crossref
Crossref
Muhammad U. Farooq, Dilip K. Pandey, Karen R. Burritt, Matthew J. Reeves & Philip B. Gorelick. 2016. Medical Practice Variations. Medical Practice Variations
259
296
.
Christian Tanislav, Sonja Milde, Sabine Schwartzkopff, Björn Misselwitz, Nicole Sieweke & Manfred Kaps. (2015) Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice. BMC Research Notes 8:1.
Crossref
Crossref
A. Groth, F. Halder, A. Fuchs, U. Maywald & T. Wilke. (2015) Unterversorgung von Vorhofflimmer-Patienten mit oralen Antikoagulanzien in DeutschlandUndertreatment of atrial fibrillation patients with oral anticoagulants in Germany: extent and causes. Der Kardiologe 9:5, pages 379-392.
Crossref
Crossref
Meytal Avgil Tsadok, Cynthia A. Jackevicius, Vidal Essebag, Mark J. Eisenberg, Elham Rahme & Louise Pilote. (2015) Warfarin Treatment and Outcomes of Patients With Atrial Fibrillation in Rural and Urban Settings. The Journal of Rural Health 31:3, pages 310-315.
Crossref
Crossref
Hemal Bhatt, Monika Safford & Stephen Glasser. (2015) Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First Century: Findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Current Hypertension Reports 17:4.
Crossref
Crossref
Souvik Sen & Katherine Willett Dahlberg. (2014) Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation. The American Journal of the Medical Sciences 348:6, pages 513-521.
Crossref
Crossref
Salvatore Rosanio, Abdul M. Keylani, Darrin C. D'Agostino, Craig M. DeLaughter & Antonio Vitarelli. (2014) Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. International Journal of Cardiology 174:3, pages 471-483.
Crossref
Crossref
Aarti A. PatelKristine OgdenMark VeermanSamir H. ModyWinnie W. NelsonNancy Neil. (2014) The Economic Burden to Medicare of Stroke Events in Atrial Fibrillation Populations With and Without Thromboprophylaxis. Population Health Management 17:3, pages 159-165.
Crossref
Crossref
Luciane Cruz Lopes, Frederick A. Spencer, Ignacio Neumann, Matthew Ventresca, Shanil Ebrahim, Qi Zhou, Neera Bhatnagar, Sam Schulman, John Eikelboom & Gordon Guyatt. (2014) Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. PLoS ONE 9:2, pages e88131.
Crossref
Crossref
Mauro Molteni & Claudio Cimminiello. (2014) Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thrombosis Journal 12:1, pages 5.
Crossref
Crossref
Muhammad U. Farooq, Dilip K. Pandey, Karen R. Burritt, Matthew J. Reeves & Philip B. Gorelick. 2016. Medical Practice Variations. Medical Practice Variations
1
40
.
Rohini Mathur, Elizabeth Pollara, Sally Hull, Peter Schofield, Mark Ashworth & John Robson. (2013) Ethnicity and stroke risk in patients with atrial fibrillation. Heart 99:15, pages 1087-1092.
Crossref
Crossref
Meytal Avgil Tsadok, Cynthia A. Jackevicius, Vidal Essebag, Mark J. Eisenberg, Elham Rahme, Karin H. Humphries, Jack V. Tu, Hassan Behlouli & Louise Pilote. (2013) Response to Letters Regarding Article, “Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation”. Circulation 128:3.
Crossref
Crossref
Neil S. Roskell, Miny Samuel, Herbert Noack & Brigitta U. Monz. (2013) Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. EP Europace 15:6, pages 787-797.
Crossref
Crossref
J. Frewen, C. Finucane, H. Cronin, C. Rice, P. M. Kearney, J. Harbison & R. A. Kenny. (2013) Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM 106:5, pages 415-424.
Crossref
Crossref
Mukaila A Raji, Matthew Lowery, Yu-Li Lin, Yong-Fang Kuo, Jacques Baillargeon & James S Goodwin. (2013) National Utilization Patterns of Warfarin Use in Older Patients with Atrial Fibrillation: A Population-Based Study of Medicare Part D Beneficiaries. Annals of Pharmacotherapy 47:1, pages 35-42.
Crossref
Crossref
Mintu P. Turakhia, Donald D. Hoang, Xiangyan Xu, Susan Frayne, Susan Schmitt, Felix Yang, Ciaran S. Phibbs, Claire T. Than, Paul J. Wang & Paul A. Heidenreich. (2013) Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. American Heart Journal 165:1, pages 93-101.e1.
Crossref
Crossref
Kamal R Mahtani, Carl J Heneghan, David Nunan, Clare Bankhead, David Keeling, Alison M Ward, Sian E Harrison, Nia W Roberts, FD Richard Hobbs & Rafael Perera. (2012) Optimal loading dose of warfarin for the initiation of oral anticoagulation. Cochrane Database of Systematic Reviews 2021:9.
Crossref
Crossref
Jenny I. Shen, Mintu P. Turakhia & Wolfgang C. Winkelmayer. (2012) Anticoagulation for atrial fibrillation in patients on dialysis. Current Opinion in Nephrology and Hypertension 21:6, pages 600-606.
Crossref
Crossref
Kaare Haurvig PalnumFrank MehnertGrethe AndersenAnnette IngemanBirgitte Randrup KrogPaul Daniel BartelsSøren Paaske Johnsen. (2012) Use of Secondary Medical Prophylaxis and Clinical Outcome Among Patients With Ischemic Stroke. Stroke 43:3, pages 802-807.
Crossref
Crossref
Roman Romero-Ortuno & Diarmuid O'Shea. (2012) Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients’ choice. Age and Ageing 41:2, pages 250-254.
Crossref
Crossref
Aurea Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis Kwong & Michael Lees. (2012) Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payerʼs Perspective. PharmacoEconomics 30:2, pages 87-101.
Crossref
Crossref
Andrew MartinRalph Stewart. (2012) Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation. Clinical Medicine Insights: Cardiology 6, pages CMC.S8204.
Crossref
Crossref
Bastian Hass, Jayne Pooley, Adrian E Harrington, Andreas Clemens & Martin Feuring. (2012) Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thrombosis Journal 10:1, pages 24.
Crossref
Crossref
Catherine J. Mercaldi, Kimberly Siu, Stephen D. Sander, David R. Walker, You Wu, Qian Li & Ning Wu. (2012) Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation. Cardiology Research and Practice 2012, pages 1-13.
Crossref
Crossref
Catherine J. MercaldiMike CiarametaroBeth HahnGeorge ChalisseryMatthew W. ReynoldsStephen D. SanderGregory P. SamsaDavid B. Matchar. (2011) Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation. Stroke 42:1, pages 112-118.
Crossref
Crossref
Isla M. Ogilvie, Sharon A. Welner, Warren Cowell & Gregory Y. H. Lip. (2017) Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thrombosis and Haemostasis 106:07, pages 34-44.
Crossref
Crossref
Kevin J. Bozic, Thomas P. Vail, Penelope S. Pekow, Judith H. Maselli, Peter K. Lindenauer & Andrew D. Auerbach. (2010) Does Aspirin Have a Role in Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty Patients?. The Journal of Arthroplasty 25:7, pages 1053-1060.
Crossref
Crossref
Sally Tyndel, Carl J Heneghan, Clare Bankhead, Yi Wan, David Keeling, Rafael Perera & Alison M Ward. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Isla M. Ogilvie, Nick Newton, Sharon A. Welner, Warren Cowell & Gregory Y.H. Lip. (2010) Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. The American Journal of Medicine 123:7, pages 638-645.e4.
Crossref
Crossref
James F. MeschiaPeter MerrillElsayed Z. SolimanVirginia J. HowardKevin M. BarrettNeil A. ZakaiDawn KleindorferMonika SaffordGeorge Howard. (2010) Racial Disparities in Awareness and Treatment of Atrial Fibrillation. Stroke 41:4, pages 581-587.
Crossref
Crossref
Timothy J KleinigThomas E KimberPhilip D Thompson. (2009) Stroke prevention and stroke thrombolysis: quantifying the potential benefits of best practice therapies. Medical Journal of Australia 190:12, pages 678-682.
Crossref
Crossref
Ajay Srivastava, Michael Hudson, Ihab Hamoud, Joao Cavalcante, Chetan Pai & Scott Kaatz. (2008) Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thrombosis Journal 6:1.
Crossref
Crossref
N U Weir. (2008) An update on cardioembolic stroke. Postgraduate Medical Journal 84:989, pages 133-142.
Crossref
Crossref
Kamakshi LakshminarayanCraig A. SolidAllan J. CollinsDavid C. AndersonCharles A. Herzog. (2006) Atrial Fibrillation and Stroke in the General Medicare Population. Stroke 37:8, pages 1969-1974.
Crossref
Crossref